Jag-this,

I do not believe Cardiogenics is "hiding something about the 2011 head-to-head study". Unless we learn otherwise, what I think happened with the head-to-head study is the company was pre-mature in making public statements regards IRB approval and the timeline for completing the study. And they compounded the seriousness of their mistake by not acknowledging the missed timeline as soon as they knew they could not meet it; these are actions that IMO an experienced management team would not have made.

IMO, a development company such as CGNH should make no public statements regards development timelines if there is any possibility that events could arise that would prevent them from meeting the timeline.

Ante